Osteosarcoma in dogs, explained honestly and in full.

Osteosarcoma is a cancer of the cells that build bone. In dogs it most often appears in the limbs, called appendicular osteosarcoma, typically near the wrist, shoulder, or knee, though it can also arise in the jaw, skull, ribs, or spine. It is largely a disease of large and giant breeds, such as Greyhounds, Rottweilers, Great Danes, Irish Wolfhounds, and similar dogs, and it is usually seen in middle-aged and older animals.

The first sign owners notice is usually lameness or a firm, painful swelling on a leg that does not improve, and is sometimes first mistaken for a sprain or arthritis. Bone cancer pain is genuinely severe, which is why controlling it is an early priority, not an afterthought.

The hardest fact about osteosarcoma is what it has usually already done. According to PubMed, at the time of diagnosis roughly 90 to 95 percent of dogs already have microscopic metastases, most often seeding the lungs, even when chest x-rays appear normal (MacEwen & Kurzman, Veterinary Clinics of North America, 1996). That is why treatment aims at two targets at once: the visible tumour in the bone, and the invisible cells that have already left it.

These numbers are hard, and we give them straight. They are medians, meaning the midpoint of a group: half the dogs lived less, and half lived longer, some by a wide margin. They describe populations, not your individual dog.

The pattern across studies is consistent: surgery on its own treats the pain and the visible tumour but does little for the spread, so survival is short, while adding chemotherapy after surgery roughly doubles or triples median survival by attacking the microscopic disease (MacEwen & Kurzman, 1996; Kozicki et al., Veterinary and Comparative Oncology, 2013). Even so, long-term survival remains the exception, and the honest framing is that chemotherapy buys good-quality time rather than a cure. Blood markers such as alkaline phosphatase and the tumour's location also shift the odds, which is a conversation for your oncologist.

If any of these numbers feel like a verdict, they should not. Read our short guide on how to read a canine cancer study to see why a median is a midpoint, not a prediction, and why the spread matters as much as the middle.

Controlling pain comes first. Bone osteosarcoma is painful, and relieving that pain is both humane and urgent. For most dogs the standard approach is amputation of the affected limb, which removes the source of the pain and the primary tumour in one step. Dogs, including large ones, generally adapt to three legs remarkably well, and most owners are surprised by how quickly their dog is comfortable and mobile again.

Where amputation is not the right choice, for example in a dog with severe arthritis in the other limbs, limb-sparing surgery or palliative radiation can control pain while keeping the leg, and medications and bone-protecting drugs help too. Your oncologist and surgeon will weigh which fits your dog.

Chemotherapy addresses the hidden spread. Because the real threat is the microscopic disease already in the lungs, chemotherapy after surgery, most often carboplatin or doxorubicin, is what changes the survival numbers above. It is generally well tolerated in dogs, with a goal of good quality of life rather than the intensity of human protocols. Not every family chooses it, and a pain-focused, surgery-only or radiation-only plan is a legitimate and compassionate path when that is right for the dog.

Osteosarcoma is one of the most important cancers in comparative oncology, because dogs and children develop a strikingly similar disease. That makes canine osteosarcoma both a proving ground for new human therapies and a cancer where dogs may benefit from that shared research. Immunotherapy approaches are under active study, and clinical trials are often available at university veterinary hospitals.

Personalized neoantigen vaccines, the approach we work on, read an individual tumour's own mutations and build a vaccine from them. In human medicine this idea produced its clearest result yet in melanoma, cutting the risk of recurrence or death by about 44 percent when added to immunotherapy in a randomised phase 2b trial (Weber et al., Lancet, 2024). That is human data, in a different and more heavily mutated cancer, and a result in people does not transfer automatically to dogs. We should be equally honest about ourselves: no cancer vaccine, including the personalized ones we design, has published canine osteosarcoma efficacy data measured against the survival benchmarks above. The science is promising, which is why we pursue it, but nothing on the horizon changes those numbers today.

A few practical steps help whatever path you choose. Ask your veterinary oncologist directly about the staging (has spread been looked for, and how), the pain plan, whether your dog is a candidate for chemotherapy or a clinical trial, and what to expect from each. If a personalized or experimental option interests you even slightly, ask that tumour tissue be preserved properly at surgery, because how tissue is handled can decide what stays possible later, following the receiving laboratory's own instructions.